These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 8741585

  • 1. Effect of clarithromycin on the bioavailability of cyclosporin in rats.
    Ohba M, Ohnishi N, Komada F, Iwakawa S, Okumura K.
    Biol Pharm Bull; 1996 May; 19(5):733-7. PubMed ID: 8741585
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of non-insulin dependent diabetes on cyclosporin A disposition in Goto-Kakizaki (GK) rats.
    Ogata M, Uchimura T, Iizuka Y, Murata R, Suzuki S, Toyota T, Hikichi N.
    Biol Pharm Bull; 1997 Sep; 20(9):1026-9. PubMed ID: 9331992
    [Abstract] [Full Text] [Related]

  • 5. Long-term levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine.
    Jin M, Shimada T, Shintani M, Yokogawa K, Nomura M, Miyamoto K.
    Drug Metab Pharmacokinet; 2005 Oct; 20(5):324-30. PubMed ID: 16272749
    [Abstract] [Full Text] [Related]

  • 6. Cyclosporin-erythromycin interaction in renal transplant patients.
    Gupta SK, Bakran A, Johnson RW, Rowland M.
    Br J Clin Pharmacol; 1989 Apr; 27(4):475-81. PubMed ID: 2655690
    [Abstract] [Full Text] [Related]

  • 7. Mechanism of decrease of oral bioavailability of cyclosporin A during immunotherapy upon coadministration of amphotericin B.
    Ishizaki J, Ito S, Jin M, Shimada T, Ishigaki T, Harasawa Y, Yokogawa K, Takami A, Nakao S, Miyamoto K.
    Biopharm Drug Dispos; 2008 May; 29(4):195-203. PubMed ID: 18240156
    [Abstract] [Full Text] [Related]

  • 8. Effect of streptozotocin-induced diabetes on cyclosporin A disposition in rats.
    Ogata M, Iizuka Y, Murata R, Hikichi N.
    Biol Pharm Bull; 1996 Dec; 19(12):1586-90. PubMed ID: 8996644
    [Abstract] [Full Text] [Related]

  • 9. Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone.
    Yokogawa K, Shimada T, Higashi Y, Itoh Y, Masue T, Ishizaki J, Asahi M, Miyamoto K.
    Biochem Pharmacol; 2002 Feb 15; 63(4):777-83. PubMed ID: 11992648
    [Abstract] [Full Text] [Related]

  • 10. Apparent dose-dependent oral absorption of cyclosporin A in rats.
    Ueda CT, Lemaire M, Gsell G, Misslin P, Nussbaumer K.
    Biopharm Drug Dispos; 1984 Feb 15; 5(2):141-51. PubMed ID: 6743782
    [Abstract] [Full Text] [Related]

  • 11. Cyclosporin A and erythromycin: a study of a drug interaction in the in situ perfused rat liver model.
    Hughes CM, Swanton JG, Collier PS.
    Biopharm Drug Dispos; 1993 Oct 15; 14(7):615-25. PubMed ID: 8251616
    [Abstract] [Full Text] [Related]

  • 12. The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers.
    Tsutsumi K, Kotegawa T, Kuranari M, Otani Y, Morimoto T, Matsuki S, Nakano S.
    J Clin Pharmacol; 2002 Oct 15; 42(10):1159-64. PubMed ID: 12362931
    [Abstract] [Full Text] [Related]

  • 13. Effects of repeated clarithromycin administration on the pharmacokinetic properties of pindolol in rats.
    Komori T, Shimoishi K, Harashima H, Otagiri M.
    Biol Pharm Bull; 1998 Dec 15; 21(12):1376-8. PubMed ID: 9881659
    [Abstract] [Full Text] [Related]

  • 14. Cyclosporin-erythromycin interaction in normal subjects.
    Freeman DJ, Martell R, Carruthers SG, Heinrichs D, Keown PA, Stiller CR.
    Br J Clin Pharmacol; 1987 Jun 15; 23(6):776-8. PubMed ID: 3606938
    [Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo antibacterial activities of clarithromycin.
    Ono T, Numata K, Nagate T, Mitsuhashi S, Inoue M.
    Chemotherapy; 1996 Jun 15; 42(3):159-69. PubMed ID: 8983882
    [Abstract] [Full Text] [Related]

  • 16. On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers.
    Reymond JP, Steimer JL, Niederberger W.
    J Pharmacokinet Biopharm; 1988 Aug 15; 16(4):331-53. PubMed ID: 3193363
    [Abstract] [Full Text] [Related]

  • 17. Concurrent clarithromycin and cyclosporin A treatment.
    Sádaba B, López de Ocáriz A, Azanza JR, Quiroga J, Cienfuegos JA.
    J Antimicrob Chemother; 1998 Sep 15; 42(3):393-5. PubMed ID: 9786481
    [Abstract] [Full Text] [Related]

  • 18. Effect of serum triglyceride concentration on the fluctuation of whole blood concentration of cyclosporin A in patients.
    Nakamura T, Kakumoto M, Sakaeda T, Nagahiro K, Ohmichi R, Yamashita K, Nishiguchi K, Hirai M, Okumura K.
    Biol Pharm Bull; 2001 Jun 15; 24(6):683-7. PubMed ID: 11411559
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Research and development of clarithromycin].
    Omura S, Morimoto S, Nagate T, Adachi T, Kohno Y.
    Yakugaku Zasshi; 1992 Sep 15; 112(9):593-614. PubMed ID: 1469609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.